POLARISqb and Scientist.com have forged a groundbreaking partnership, introducing the Quantum-Aided Drug Design (QuADD) platform, marking a significant leap in drug discovery technology. POLARISqb, pioneers in quantum-enabled molecular optimization tools for drug discovery, collaborated with Scientist.com, the leading online marketplace for outsourced research. This collaboration allows Scientist.com users access to POLARISqb’s QuADD platform, leveraging quantum computing to expedite the creation of optimized molecular libraries for drug design within days.
POLARISqb’s QuADD is a software platform utilizing quantum annealing computers, completing calculations over 500 times faster than traditional computers. It translates the molecular library building problem into an optimization challenge, providing a library of potential drug candidates targeting specific binding pockets in 1-3 days. Bill Shipman, CTO and Co-Founder of POLARISqb, expressed enthusiasm about working with Scientist.com to extend the platform to a broad network of researchers, enhancing the search for novel drug candidates.
Scientist.com’s CEO, Kevin Lustig, highlighted their commitment to supporting cutting-edge drug research innovators like POLARISqb. The QuADD software, by significantly accelerating the discovery of new drug candidates, holds promise for addressing hundreds of human diseases. POLARISqb, with its QuADD platform, combines quantum and cloud computing, artificial intelligence, and machine learning, offering a transformative approach to drug discovery. For further details, readers can access the original press release provided by the company here.
January 5, 2024